Patrys Limited announced that it has completed animal pharmacokinetic studies for both its development-stage deoxymabs; its lead asset PAT-DX1, and the full sized IgG antibody, PAT-DX3, which was added to the portfolio in September 2020. Both antibodies have shown favorable PK profiles with anticipated differences (due to their different sizes) potentially opening up different clinical applications for the two assets. Pharmacokinetic profiling follows a drug on its path through the body, from its absorption into the bloodstream, its distribution to the tissues, and finally its elimination via either metabolism or excretion (ADME). An understanding of the pharmacokinetics of investigational drugs is essential for establishing appropriate dosing regimens, and is one element of the data package required to initiate the clinical development of PAT-DX1 in H1 2022. The company has completed several studies in animal models of cancer which indicate that PAT-DX1 is rapidly removed from the blood due to its rapid accumulation in tumours. These more recent pharmacokinetic studies of PAT-DX1 and PAT-DX3 were conducted in healthy animals. PAT-DX1, because it is an antibody fragment, was rapidly cleared from circulation. As expected, PAT-DX3, because is a full-sized IgG antibody, resided in circulation for a significantly longer period of time. This is consistent with the unique mechanism of action of the PAT-DX1 and PAT-DX3 antibodies and will further inform the dosing regimen both as single agent therapeutics as well as broader applications. These differences in pharmacokinetic profiles may make PAT-DX1 and PAT-DX3 better suited for different clinical applications. These studies also provided encouraging data on the potential safety profiles of PAT-DX1 and PAT- DX3 as they were well-tolerated, with no body weight loss or visible clinical side effects observed.